Stem Cell Therapy Market Size, Outlook on Key Growth Trends, Factors and Forecast to 2026 – ReportsPioneer

New Jersey, United States, The report is a brilliant presentation of critical dynamics, regional growth, competition, and other important aspects of the Stem Cell Therapy Market. The factual, unbiased, and thorough assessment of the global Stem Cell Therapy market presented in the report assures players of access to much-needed information and data to plan effective growth strategies. The report has made a brilliant attempt to provide a comprehensive research study on industry value chain, major companies, deployment models, and key opportunities, drivers, and restraints of the global Stem Cell Therapy market. It shows how the global Stem Cell Therapy market will advance or lack growth during each year of the forecast period. Readers are offered with detailed and near-accurate predictions of CAGR and market size of the global Stem Cell Therapy market and its important segments.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Besides an exhaustive evaluation of leading trends of the global Stem Cell Therapy market, the report offers deep analysis of market development and future market changes. It includes Porters Five Forces analysis, PESTLE analysis, and qualitative as well as quantitative analysis for complete research on the global Stem Cell Therapy market. It closely focuses on technological development of the global Stem Cell Therapy market and its impact on the business of market players. With the help of the report, players will be able to become familiar with production and consumption trends of the global Stem Cell Therapy market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=RPN&utm_medium=009

Top 10 Companies in the Global Stem Cell Therapy Market Research Report:

Vendor Landscape Analysis

The competitive landscape of the global Stem Cell Therapy market is extensively researched in the report. The analysts have largely concentrated on company profiling of major players and also on competitive trends. All of the companies studied in the report are profiled on the basis of production, revenue, growth rate, markets served, areas served, market share, and market growth. The report will help readers to study significant changes in market competition, the level of competition, and factors impacting future market competition. It discusses important target market strategies that leading players are expected to adopt in future. In addition, it throws light on future plans of key players.

Market Segmentation

The report offers deep insights into leading segments of the global Stem Cell Therapy market and explains key factors helping them to collect a larger share. It provides accurate growth rate and market size achieved by each segment during the forecast period. This will help players to identify lucrative segments and plan out specific strategies to gain maximum profit from them. The report also includes sales growth, revenue, and price changes observed in important segments. Most importantly, the segmental analysis equips players with useful information and data to make the best of opportunities available in different segments.

Regions Covered in the Global Stem Cell Therapy Market:

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=RPN&utm_medium=009

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=RPN&utm_medium=009

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]marketresearch.com

See original here:
Stem Cell Therapy Market Size, Outlook on Key Growth Trends, Factors and Forecast to 2026 - ReportsPioneer

For Kaus, getting back on court is next step in recovery – Mankato Free Press

Justin Kaus has officiated thousands of basketball games in the last couple of decades, but on Friday night, in the locker room a few minutes before taking the court at Fitzgerald Gym, his resting heart rate was a rapid 118 beats per minute.

Its been a long time since Ive been that nervous and had that much adrenaline for a (junior-varsity) game, Kaus said, gathering with friends later Friday night to celebrate the way basketball officials often do on the weekend. It was awesome.

Kaus returned to the basketball court Friday for the first time since early February, having battled a form of leukemia that halted his professional and athletic career and nearly took his life.

It was great, he said, flexing some stiff muscles and joints. The interaction with coaches, talking with fans, interacting with the players ... you forget how much fun and rewarding that it.

It was more than 14 months since Kaus, 44, went to the clinic, feeling run down and with little energy or strength. He was diagnosed with a sinus infection, but two weeks passed, with stronger antibiotics, and he wasnt feeling any better.

He scheduled a visit to another doctor, who put him through a more extensive examination. He had blood drawn, and, as he was driving home, his doctor called and told him to get to the emergency room.

His hemoglobin level was dangerously low, and Kaus was taken by ambulance to the hospital in Rochester.

I went from thinking I had a sinus infection to having blood cancer in about 6 hours, Kaus said.

Thus began the yearlong process of trying to survive a diagnosis of primary myelofibrosis, a treatable form of leukemia. He continued his normal routine of work and officiating basketball games for a couple of months, trying not to get too worn down.

By February, after finding a couple of perfect donors for a bone-marrow transplant, the treatment became more rigorous and dangerous.

There was a round of chemotherapy in mid-February, followed by a stem cell transplant on Feb. 28. He was told to expect at least 100 days in the hospital, but that time more than doubled when he had to have his spleen removed in March. He developed an infection that required the removal of most of his colon, forcing a lifesaving surgery on May 25.

The doctor told me that if I didnt have my colon removed, it would likely burst, Kaus said. At that point, there would have been nothing more they could do for me.

There were a few weeks during the summer that he cant remember. At one point, he shut off his cell phone after staring at it one day, not sure what he was supposed to do with it. His friends stayed in touch through an online diary, written by his girlfriend, Delight Simpson.

In May, hundreds of Kaus friends gathered for a fundraiser, collecting thousands of dollars to help him with his monthly bills and extra expenses and exchanging hope for Kaus.

I cant thank people enough, he said, getting momentarily choked up with emotion. The support Ive received from my family, my work family, my basketball family has been unbelievable.

Kaus said that since that surgery, his recovery has been rapid and remarkable. Its about what he had originally been told had he not had any complications. Hes had more than 100 blood transfusions, and ironically, he now goes in a couple of times each month to have some blood removed.

After what Ive been through, its hard to watch them just throw that blood away, he said.

He weighed 153 pounds when the treatments began but slipped to 98 pounds. Hes worked hard to get his weight back to near normal, and hes done of lot of rehab work to regain strength. He was unable to lift 2 pounds at his most dire times. He still sees a doctor a couple of times each month, but those visits have become less frequent.

Until recently, he had to rely on Simpson, his daughter, Taylor, and his mom, Sally, to get around, but now hes driving again.

When he started rehab, he couldnt lift 10 pounds on the single-leg press, but hes now up to 125. Hes always been active, participating in sports, and his conditioning has slowly returned.

It felt so good to see him there, said Ben Kaus, Justins cousin and officiating partner on Friday. There was such a shock factor (a year ago) when we found out about his condition, and it took a while to sink in. For a while, we didnt know if Justin was going to be around much longer.

But at one of the visits, when it didnt look very good, he told us that he was going to make it. His positive attitude is what made the difference. Justin has always been like a big brother to me, and its great to have him back.

On Feb. 28, which will be one year from the stem-cell transplant, Kaus will have a checkup to see if the cancer is gone or he needs more treatment. Hell also know shortly after that if he needs to continue with colostomy and ileostomy bags or he can have surgery to reattach his colon to the digestive tract.

Until then, hes going to continue to increase his work hours and officiate basketball as much as his body can tolerate. He wanted to get that first assignment out of the way to see how he felt, then he can plan the next couple of months. Being on the court is as much of a mental triumph as a physical milestone.

In August, I had pretty much written off this season, he said. In early December, it was my 40th physical therapy session in Mankato, my physical therapist suggested that I talk with some coach and go to a scrimmage to simulate basketball movements.

Its the coolest thing to be back on the court, he said. Ive gotten so many messages and words of encouragement and support from the start to this point. This was another step in getting back to normal, and its something Ive worked hard for.

Its never been about me, but the camaraderie being around other officials and telling stories and talking about the games has been very therapeutic. We dont have to (officiate basketball games). We do it because we still enjoy the games and we want to give something back. I hope the coaches, the players, the fans appreciate what we do, but in the end, all that matters is were spending time in the gym, around a game that we love.

Follow Chad Courrier on Twitter @ChadCourrier.

Continued here:
For Kaus, getting back on court is next step in recovery - Mankato Free Press

Animal Stem Cell Therapy Market: Growth Trends, Sales Outlook, Revenue, Market Toppers, End-Users, Major Regions – ReportsPioneer

Animal Stem Cell Therapy market research report provides the details about Industry Chain structure, Market Competition, Market Size & Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development & Trends, Regional Forecast, Company & Profile and Product & Service.

Animal Stem Cell Therapy market research report also gives information on the Trade Overview, Policy, Regional Market, Production Development, Sales, Regional Trade, Business Operation Data, Market Features, Investment Opportunity, Investment Calculation and other important aspect of the industry.

Request a Sample of Animal Stem Cell Therapy Market Research Report with 117 pages and Analysis of Top Key Players at https://www.insidemarketreports.com/sample-request/4/133116/Animal-Stem-Cell-Therapy

The main objectives of the research report elaborate the overall market overview on Animal Stem Cell Therapy market dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies & regulations, etc. Major companies, company overview, financial data, products and services, strategy analysis, key developments market competition, industry competition structure analysis, SWOT Analysis, etc.

Further Animal Stem Cell Therapy market research report provides regional marketanalysis with production, sales, trade & regional forecast. it also provides market investment plan like product features, price trend analysis, channel features, purchasing features, regional & industry investment opportunity, cost & revenue calculation, economic performance evaluation etc.

The Animal Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

Report Scope

The tunnel ventilation market has been segmented based on different types and application. In order to provide a holistic view on the market current and future market demand has been included in the report.

Major players covered in this report are MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics etc.

Major Points covered in this report are as below

Owning our reports and subscribing our eco-system will help you solve the following issues:

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This help our client to invest or divest their resources.

It is extremely crucial to have a fair understanding of market sentiments for a strategy. Our insights help to have a hawk-eye view on a market sentiment. We keep this surveillance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Our research ranks investments centers of market by considering their future demands, returns and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Our research and insights help our clients in identifying compatible business partners.

Buy this report online athttps://www.insidemarketreports.com/buy-now/4/133116/Animal-Stem-Cell-Therapy/single

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Here is the original post:
Animal Stem Cell Therapy Market: Growth Trends, Sales Outlook, Revenue, Market Toppers, End-Users, Major Regions - ReportsPioneer

Father-of-three raises cash for last chance MS treatment – Wakefield Express

A father-of-three has launched a fundraiser for medical treatment that he hopes will help tackle his debilitating illness.

Phil Swindin, from Darrington, was diagnosed with Multiple Sclerosis in 2004, and has suffered major problems with his health ever since.

His symptoms have now escalated, leaving him unable to walk more than a metre without support, and relying on caffeinated drinks for short bursts of energy.

He hopes to travel to a private facility in Mexico for a new type of treatment known as Autologous Haematopoietic Stem Cell Transplantation (AHSCT), which has been linked with improvements in MS.

Phil said: Living with MS is constant and terrifying, as you just get more and more disabled and whatever you do very little can be done.

My MS symptoms have fluctuated and reared its ugly head at the most inappropriate times and limited my normal physical or mental ability.

Its caused major hidden problems in mobility, mental health, energy levels and so many other symptoms.

I long to do simple things like doing things with my kids, playing football or going for a walk but its out of the question.

All other avenues have failed so Im left with only one option, to fundraise for private treatment.

Phil and his wife Alison launched the fundraiser last month, and have already raised more than 28,000.

The couple also hope to organise a ball in the Spring to help boost funding,

Alison said: People have just been wonderful. People who we havent spoken to for years have been in touch and their words of support are fantastic.

It sort of feels much more achievable than when we started it. Were just trying to keep it moving, with more things happening all the time.

Phils treatment is currently booked for April, but will have to be postponed if the funds are not raised before then.

Phil has also been supported by Ackworth mum-of-two Kate Dawson, who successfully underwent the treatment in 2017 and described the results as life-changing.

Visit gofundme.com/f/transplant4phil to find out more.

Read more from the original source:
Father-of-three raises cash for last chance MS treatment - Wakefield Express

Former SeaChange actor Tom Long has died, five months after being cleared of cancer, & more in News in 5. – Mamamia

Its absolutely incredible to think back to when we first started, McGrath said.

CA and the SCG Trust came to us and offered us the SCG Test in remembrance of Jane and to support the foundation and my family.

What it has grown into now is absolutely incredible.

If what weve done here has an impact in other places for other charities then its absolutely brilliant.

The McGrath Foundation aimed to raise $1.6 million from the Sydney Test between Australia and New Zealand, to take their tally of nurses from 135 to 147.

They were still in pursuit of reaching their goal by late on day three, with takings at the ground up on last year.

This years Test has been played in the backdrop of the bushfire emergency that engulfs the nation.

It was notable on Sunday that as the smoke began to be seen at the SCG, the pink boundary signs were one of the few things to shine through the lingering Sydney haze.

For the McGrath Foundation that hits close to home too.

Three-quarters of their nurses are in rural and regional areas while McGraths own childhood home of Narromine is among the most drought-affected in NSW.

I heard a story of lady whose family is impacted by the fires, foundation ambassador Tracy Bevan said.

She left her family, rode a bike, got on a boat and she went on the boat for chemotherapy.

She knew she had to go and have that treatment because of the impact of that insidious disease.

Wildlife official Mike Williams has been appointed to lead the recovery on Kangaroo Island from the devastating bushfires.

The National Parks and Wildlife Service senior executive has been named the local recovery coordinator to support islanders as they come to grips with their needs over the coming weeks and months.

This is an unprecedented tragedy for the Kangaroo Island community, who are now facing a recovery effort on a scale never seen before on the island, SA Human Services Minister Michelle Lensink said.

Mr Williams will work with locals to coordinate recovery measures and help residents, primary producers, tourism operators and other local businesses navigate a way forward.

His appointment recognises the unique challenges facing Kangaroo Island as it embarks on the process of recovery, including geographic isolation, losses relative to population, impacts on local economic activity and community wellbeing.

There are fears as many as half of South Australias Kangaroo Islands koala population has been wiped out. Report in 7NEWS at 6pm. #KIfires #7NEWS https://t.co/DgeaVRKBpw

7NEWS Sydney (@7NewsSydney) January 5, 2020

Read more:
Former SeaChange actor Tom Long has died, five months after being cleared of cancer, & more in News in 5. - Mamamia

Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More – DocWire News

This weeks Cardio Round-up features a look back at what you may have missed during the holidays, as well as some of the big 2019 cardiology stories.

The past year saw some big stories like the Apple Heart study, presented at ACC.19, which essentially validated the ability of a wearable device (an Apple iWatch) equipped with a tachogram-tracking algorithm was able to detect pulse irregularities associated with atrial fibrillation. Icosapent ethyl also featured prominently, gaining an FDA approval for the reduction of cardiovascular disease risk as an add-on to statin therapy in high-risk patients with hypertriglyceridemia. Dapagliflozin (highlighted in the DAPA-HF study) also was shown to be an effective treatment for heart failure in both diabetic and non-diabetic patients.

2019 In Cardiology: Apple Heart Study Lands; Icosapent Ethyl Gets FDA Nod for New Indication; Dapagliflozin For Nondiabetics; and More

A new observational study published inEuropacesuggests it is possible to monitor and predict individual progression ofatrial fibrillation (AFib) using pacemakers or defibrillators.We aimed to study the progression of AER in individual patients with implantable devices and AFib episodes, the paper authors wrote. The study results indicated that the slope of AAR changes during the progression of AFib showed patient-specific patterns correlating with the time-to-completion of AER (R2 = 0.85). This technology opens up enormous possibilities in personalized medicine for AFib patients because it allows us to determine the progression rate of the arrhythmia in each individual and to optimize the timing of medical intervention with current treatment options, one of the researchers said in a press release.

Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation

A research team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardiac progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release. Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells.

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment

Diabetes mellitus is an independent predictor for heart failure, according to the findings of a study published inMayo Clinic Proceedings. In this study, using the Rochester Epidemiology Project, researchers assessed the long-term impact ofdiabeteson the development of heart failure by including 116 study subjects with diabetes, who were matched 1:2 based on age, hypertension, sex, coronary artery disease and diastolic with 232 participants without diabetes. The results showed that that diabetes is an independent risk factor for the development of heart failure. Over the duration of 10 years, 21% of participants with diabetes developed heart failure, independent of other causes. The researchers observed that by comparison, only 12% of patients without diabetes developed heart failure. The key takeaway is that diabetes mellitus alone is an independent risk factor for the development of heart failure, wrote one of the authors.

Diabetes is an Independent Predictor for Heart Failure

A new study suggests that regularly getting a good nights sleep isnt just a helpful overall health recommendation but is also an essential way to keep risk for heart disease and stroke down. The paper, published in theEuropean Journal of Cardiology, included more than 300,000 participants initially free of cardiovascular disease (CVD) from UK Biobank. According to the results, there were 7,280 documented cases of incident CVD (4,667 coronary heart disease and 2,650 stroke) cases. Participants with a sleep score of 5 had a 35% reduced risk for CVD, a 34% reduced risk for coronary heart disease, and a 34% reduced risk for stroke when compared to participants with a score of 0-1.As with other findings from observational studies, our results indicate an association, not a causal relation, one of the authors said in a press release. However, these findings may motivate other investigations and, at least, suggest that it is essential to consider overall sleep behaviors when considering a persons risk of heart disease or stroke.

Getting Quality Sleep, and the Right Amount, Can Offset Genetic Susceptibility for Heart Disease and Stroke Risk

View post:
Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More - DocWire News

My agonising two-year wait for a stem-cell donor after being diagnosed with leukaemia – The Telegraph

There is also another option on the table: a technology called haplo-identical, where they could use the stem cells from my brother, who is a 50 per cent match.

But it shouldnt have been this hard to find a match, and thats whyI started my campaign to sign more people up to the transplant list.I want to make a difference for other people who have to go through this.

If I dont make it, I want to leave a legacy that the children can look at when theyre older and know that Mummy did everything she could to fight this thing. There can only be one winner with this disease, and it needs to be me.

As told to Jessica Salter

Leukaemia Care is one of three charities supported by this years Telegraph Christmas Charity Appeal. Our others are Wooden Spoon, which works with the rugby community to raise money for disabled and disadvantaged children,and The Silver Line, a telephone support service for lonely elderly people. To donate,visit telegraph.co.uk/charity or call 0151 284 1927 before the end of January

More:
My agonising two-year wait for a stem-cell donor after being diagnosed with leukaemia - The Telegraph

Top 10 Parkinson’s Stories of 2019 – Parkinson’s News Today

Parkinsons News Today keeps you up-to-date with research into Parkinsons disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinsons, results of clinical and pre-clinical trials, and key findings from Parkinsons research around the globe.

We look forward to bringing more such news to those with Parkinsons, their family, friends and caregivers throughout 2020.

Here are our 10 most-read stories of 2019, with a short summary of what makes each one relevant to the Parkinsons community.

No. 10 Active Form of Vitamin B12 Found to Prevent Neurodegeneration in Study of Animal Models

A study found that an active form of the vitamin B12 called AdoCbl can ease the effects of dopamine loss that occurs in Parkinsons disease. Using cell lines and several animal models, researchers showed that by reducing LRRK2 enzyme activity, AdoCbl limits the death of dopamine-producing nerve cells, thereby preventing the appearance of symptoms associated with neurodegeneration. Overactivity of LRRK2 is linked to the development of a hereditary form of Parkinsons. AdoCbl is already an FDA-approved compound, and could be used as a basis to develop new therapies to combat hereditary Parkinsons associated with pathogenic variants of the LRRK2 enzyme, according to Iban Ubarretxena, director of theBiofisika Institute and a study co-author.

No. 9 Onstryv Now Approved for Parkinsons Patients in Canada

Canadian Parkinsons disease patients now have access to Onstryv (safinamide), also known as Xadago. Onstryv increases the amount of active dopamine in the brain by both preventing the enzyme that breaks dopamine down from doing so, and by blocking that enzyme from entering cells. Other available treatments cause debilitating fluctuations between normal motor function (called on episodes) and poorer motor function (off periods) as their effects ebb and flow. Four placebo-controlled Phase 3 trials showed that the combination of Onstryv and levodopa led to more on and fewer off periods, and improved motor function in patients. The approval of [Onstryv] in Canada is a step forward for patients who need new treatment options for Parkinsons disease, said Roberto Tascione, CEO of Zambon, one of the companies involved in commercializing this medication.

Xadago was approvedby theU.S. Food and Drug Administration in March 2017 to improvemotor functionin Parkinsons patients who experience off periods while on treatment withlevodopaand/or Lodosyn (carbidopa).

No. 8 Plant Antioxidant Seen to Aid Mitochondria and Ease Motor Problems in Early Parkinsons Study

A pre-clinical study conducted in China showed that alpha-arbutin, an antioxidant found in plants such as the blueberry, might restore mitochondrial function in nerve cells and ease the motor disabilities associated with Parkinsons disease. Treatment with alpha-arbutin partially restored mitochondrial function in nerve cells undergoing oxidative stress (mitochondria act as a cells power house). It also restored these cells ability to remove toxic waste products. Feeding alpha-arbutin to flies carrying a mutated gene known to trigger Parkinsons significantly eased several Parkinsons-like symptoms. Naturally derived-antioxidants might serve as a new class of therapeutic options for [Parkinsons disease], the researchers wrote.

No. 7 Stem Cell Transplants Could Significantly Improve Parkinsons Treatment, Study Suggests

Replacing damaged cells in Parkinsons disease with dopamine-producing stem cells could easemotor symptoms and reduce or eliminate the need for pharmaceutical medicines. As current disease therapies lose their efficacy over time, stem cell therapy might revolutionize Parkinsons treatment, its researchers said.A single surgery could potentially provide a transplant that would last throughout a patients lifespan, reducing or altogether avoiding the need for dopamine-based medications, said Claire Henchcliffe MD, PhD, and Malin Parmar, PhD, co-authors of a study on the benefits of stem cell therapy. However, there are several biological, practical, and commercial hurdles that need circumventing for this to become a routine therapy, according to the editors of theJournal ofParkinsons Disease.

No. 6 Bacteria in Gut Can Promote Parkinsons by Altering Brains Immune Reactions, Study Says

A study found evidence of interaction between the brain and the gut in Parkinsons, in which Gram-negative bacterial infections in the gut trigger an immune response that damages nerve cells. Gut microorganisms are known to communicate with the central nervous system, andstudies suggest that harmful proteins related to Parkinsons may spread to the brain from the gut.Scientists at theUniversit de Montral showed that Gram-negative bacteria, particularly those related to gut infections, triggered an immune response in cells taken from mice. They then showed that mice bred without thePINK1 gene (making them resistant to Parkinsons-like symptoms), when infected with these bacteria, displayed an immune response that led to such symptoms. Mutations in the PINK1 gene cause damage to the mitochondria in brain cells, and are linked to early onsethereditary Parkinsons. The work provides evidence that intestinal infection acts as a triggering event in Parkinsons, andhighlighted the relevance of a gut-brain connection in this disease.

No. 5 Next 20 Years Expected to Bring Message of Hope to Parkinsons Patients, Review Study Finds

By reviewing the past 20 years of research into Parkinsons disease, two scientists see a strong potential for breakthroughs in how this disease is approached over the next 20 years. The review cited developments in better animal models, greater understanding of molecular mechanisms and risk factors, and advances in available and potential therapies as reasons for hope. Among highlights of many advances listed are: 1) the adaptation of existing medicines used in other diseases to treat Parkinsons (drug repurposing); 2) targeting non-motor features such as cognition, speech and balance difficulties that often precede motor symptoms; 3) the use of nanoparticles to block the formation of toxic alpha-synuclein clusters; and, 4) emerging evidence of a link between harmful gut bacteria and brain inflammation. The review also stressed the importance of future trials to test combination therapies.

No. 4 Physical Activity, Coffee, Moderate Alcohol Consumption Protect Against Disease Progression, Study Reports

Good news for lovers of sports, caffeine, and happy hours all of these things, in moderation, may help slow the onset of symptoms of Parkinsons disease. Although how exactly these lifestyle factors affect disease progression remains poorly understood, they correlate strongly with better patient outcomes. Conversely, smoking, heavy drinking and no consumption of alcohol at all were linked to considerably worse outcomes. The study, published in the journalMovement Disorders, needs to be replicated to strengthen the usefulness of its findings. Nonetheless, the work suggests that multiple lifestyle factors potentially modify the rate of symptom progression, its researchers wrote.

No. 3 Dietary Supplement Eases Parkinsons Symptoms, Improves Dopamine Function, Study Shows

The antioxidant dietary supplement N-acetyl-cysteine (NAC) may improve dopamine function and ease Parkinsons disease symptoms, according to one study. The body uses NAC to produce an antioxidant called glutathione (GSH), which it uses to prevent the oxidative stress that leads to cell death. Damage due to oxidative stress within dopamine-producing neurons is a key clinical feature of Parkinsons. A trial (NCT02445651), conducted by researchers atThomas Jefferson University in Philadelphia, showed that NAC supplementation significantly eased both motor andnon-motor symptoms among 42 Parkinsons patients (21 men and 21 women). These results need to be confirmed in larger and placebo-controlled studies, but offer an encouraging start to a potential low-cost therapy.

No. 2 Low Vitamin D Levels Linked to Added Falls, More Sleep Problems, Depression, Study Shows

Low levels of vitamin D were associated with more falls, and greater problems withinsomnia, anxiety, anddepressionin people withParkinsons disease, according to a study by Chinese researchers. Vitamin D deficiency has often been seen in people with Parkinsons, but its relationship to the disease remains controversial. This study, by researchers at theSecond Affiliated Hospital of Soochow UniversityandSoochow University, is one of the few to measure both motor and non-motor outcomes. By conducting detailed clinical evaluations in 182 Parkinsons patients, as well as 185 healthy controls, the group found that low levels of vitamin D were more common in Parkinsons patients than in healthy people, and that vitamin D supplements may ease the diseases nonmotor symptoms.

No. 1 Oral Magnesium Compound Able to Reach Brain Seen to Slow Motor Decline, Neuronal Loss in Early Study

Our years most-read story was of an early stage studyreporting that a type of oral magnesium could enter the brain and ease motor symptoms and nerve cell loss in a mouse model of Parkinsons disease. Mice given magnesium-L-threonate, which can cross the blood-brain barrier (a semipermeable membrane that protects the brain from the outside environment) reduced the loss of dopamine-producing neurons, slowed the decline in motor function, and limited the oxidative stress that is associated with Parkinsons. It is important to note that while magnesium-L-threonate provided therapeutic benefits, magnesium sulfate the first choice as a clinical magnesium supplement did not. [T]he combination of [magnesium] with an agent that promotes its transportation to the brain is essential for the neuroprotection of this element, the studys scientists wrote.

***

AtParkinsons News Today we hope these stories and our reporting throughout 2020 help to better inform and improve the lives of everyone affected by Parkinsons.

We wish all our readers a happy 2020.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

See the rest here:
Top 10 Parkinson's Stories of 2019 - Parkinson's News Today

Cell & Advanced Therapies Supply Chain Management Markets, Forecast to 2030 – In 2018, Approx $13Bn Was Invested in This Domain, Representing a 73%…

DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions" report has been added to ResearchAndMarkets.com's offering.

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030

report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. An Introduction to Cell and Advanced Therapies3.2.1. Classification of Advanced Therapy Medicinal Products3.2.2. Current Market Landscape3.3. Cell and Advanced Therapies Supply Chain3.3.1. Key Processes3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management3.4.1. Cell Orchestration Platform3.4.2. Enterprise Manufacturing System3.4.3. Inventory Management System3.4.4. Laboratory Information Management System3.4.5. Logistics Management System3.4.6. Patient Management System3.4.7. Quality Management System3.4.8. Tracking and Tracing System3.5. Growth Drivers and Roadblocks3.6. Emergence of Digital Technologies in Supply Chain Management3.6.1. Blockchain Technology3.6.2. Internet of Things3.6.3. Augmented Reality3.6.4. Big Data Analytics3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape4.2.1. Analysis by Type of Software Solution4.2.2. Analysis by Key Specification and Benefit4.3.3. Analysis by Application4.3.4. Analysis by End User4.3.5. Analysis by Mode of Deployment4.3.6. Analysis by Scale of Management4.3.7. Analysis by Regulatory Certifications / Accreditations4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape4.2.1. Analysis by Year of Establishment4.2.2. Analysis by Location of Headquarters4.2.3. Analysis by Size of Company4.3.4. Analysis by Support Services Offered4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES6.1. Chapter Overview6.2. Brooks Life Sciences6.2.1. Company Overview6.2.2. Financial Information6.2.3. BiobankPro: Software Description6.2.4. Recent Developments and Future Outlook6.3. Cryoport6.3.1. Company Overview6.3.2. Financial Information6.3.3. Cryoportal: Software Description6.3.4. Recent Developments and Future Outlook6.4. MasterControl6.4.1. Company Overview6.4.2. MasterControl Platform: Software Description6.4.3. Recent Developments and Future Outlook6.5. SAP6.5.1. Company Overview6.5.2. Financial Information6.5.3. SAP S/4HANA: Software Description6.5.4. Recent Development and Future Outlook6.6. Savsu Technologies6.6.1. Company Overview6.6.2. Financial Information6.6.3. evo Cold Chain 2.0: Software Description6.6.4. Recent Development and Future Outlook6.7. TraceLink6.7.1. Company Overview6.7.2. Financial Information6.7.3. Digital Supply Chain Platform: Software Description6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS7.1. Chapter Overview7.2. Supply Chain Orchestration Platforms7.2.1. Key Functions of Supply Chain Orchestration Platforms7.2.2. Advantages of Supply Chain Orchestration Platforms7.2.3. Supply Chain Orchestration Platform Implementation Strategies7.3. Supply Chain Orchestration Platform: Trends on Twitter7.3.1. Scope and Methodology7.3.2. Historical Trends in Volume of Tweets7.3.3. Popular Keywords7.4. Key Industry Players7.4.1. Be The Match BioTherapies7.4.2. Clarkston Consulting7.4.3. Haemonetics7.4.4. Hypertrust Patient Data Care7.4.5. Lykan Bioscience7.4.6. MAK-SYSTEM7.4.7. sedApta Group7.4.8. Stafa Cellular Therapy7.4.9. Title 21 Health Solutions7.4.10. TrakCel7.4.11. Vineti

8. FUNDING AND INVESTMENT ANALYSIS8.1. Chapter Overview8.2. Types of Funding8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances8.3.1. Analysis by Number of Funding Instances8.3.2. Analysis by Amount Invested8.3.3. Analysis by Type of Funding8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions8.3.5. Most Active Players: Analysis by Amount Invested8.3.6. Most Active Investors: Analysis by Participation8.3.7. Geographical Analysis by Amount Invested8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS9.1. Chapter Overview9.2. Partnership Models9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships9.3.1. Analysis by Year of Partnership9.3.2. Analysis by Type of Partnership9.3.3. Analysis by Partner's Focus Area9.3.4. Analysis by Type of Software Solution9.3.5. Most Active Players: Analysis by Number of Partnerships9.3.6. Analysis by Regions

10. PLATFORM UTILIZATION USE CASES10.1. Chapter Overview10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases10.2.1. Analysis by Year of Utilization10.2.2. Analysis by User's Focus Area10.2.3. Analysis by Type of Software Solution10.2.4. Most Active Players: Analysis by Number of Utilization Instances10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS11.1. Chapter Overview11.2. Cell and Advanced Therapies Value Chain11.2. Cell and Advanced Therapies Value Chain: Cost Distribution11.3.1. Donor Eligibility Assessment11.3.2. Sample Collection11.3.3. Manufacturing11.3.4. Logistics11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS12.1. Chapter Overview12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Methodology13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-203013.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-203013.3.2. Cost Saving Potential in Sample Collection, 2019-203013.3.3. Cost Saving Potential in Manufacturing, 2019-203013.3.4. Cost Saving Potential in Logistics, 2019-203013.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST14.1. Chapter Overview14.2. Key Assumptions and Forecast Methodology14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-203014.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-203014.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-203014.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-203014.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-203014.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Thermo Fisher Scientific15.2.1. Company Snapshot15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager15.3. Cell and Gene Therapy Catapult15.3.1. Company Snapshot15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer15.4. McKesson15.4.1. Company Snapshot15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development15.5. TrakCel15.5.1. Company Snapshot15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS16.1. Chapter Overview16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/2c3a4h

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/cell--advanced-therapies-supply-chain-management-markets-forecast-to-2030---in-2018-approx-13bn-was-invested-in-this-domain-representing-a-73-increase-in-capital-investments-compared-to-2017-300980815.html

SOURCE Research and Markets

See the original post here:
Cell & Advanced Therapies Supply Chain Management Markets, Forecast to 2030 - In 2018, Approx $13Bn Was Invested in This Domain, Representing a 73%...

ASTRONOMICAL ODDS: Stem cell recipient and her donor both from Ottawa – Ottawa Sun

Colleen LeCours lay in a hospital bed at the General campus of The Ottawa Hospital on August 12, 2016, waiting for the only thing that could save her life a stem cell transplant from a stranger.

The donor could be anywhere in the world if a related blood donor cant be found, the call to find a match goes out to registries all over the globe and the donated stem cells are rushed across international borders.

What LeCours didnt know is that her donor, an 18-year-old Carleton University student named Timothy White, was just one floor below. Similarly, White didnt know that his recipient was in the same hospital.

There are currently more than 450,000 people on the Canadian Blood Services Stem Cell Registry formerly known as OneMatch and 36 million on affiliated international registries. Still, some people never find a match. There are more than 900 Canadians in need of a transplant who have not found a match anywhere in the world.

What were the odds that the match for LeCours, now 57, would be found in the same city?

Astronomical, she said.

The chances that White would even ever be asked to donate were also very low only about one in a thousand. After he agreed to donate, he was not told where the recipient might be. I was told the recipient could be anywhere. They could be in Africa, said White, now 22 and a recent graduate in computer science.

White had signed up for the registry through a cheek swab booth at ComiCon less than six months earlier. A smart place to recruit would-be stem cell donors, he notes. The optimal donor is a male between the age of 17 and 35 and thats the ComiCon demographic.

He decided to register as a potential donor because he grew up in the scouting movement. One of the main philosophies is to do a good turn every day, he said.

The donation was a non-surgical procedure in which Whites blood was removed though a needle, the stem cells were separated from his blood and the remaining blood components returned to his body through another needle. The procedure started at about 8 a.m. and was over by about 5 p.m.

I figured if I gave someone a day for a thousand more days (of life) then I felt it was a fair trade. I have many years of life. Why not spend one day? said White.

LeCourss medical journey started in 2009 with an emergency room visit for abdominal pain. She was eventually diagnosed with Stage 4 follicular lymphoma, a blood cancer that affects infection-fighting white blood cells. At the time, LeCours was working for Gov.-Gen. Michalle Jean and was able to stay on the job most of the time during her six months of treatment.

Four years later, the lymphoma returned. It was back again two years after that, in a more aggressive form. The only treatment was stem cell transplant.

There are two main kinds of stem cell transplants autologous and allogenic. In an autologous transplant, stem cells are collected from a patients own blood and reintroduced after being treated to remove cancer cells. In an allogenic stem cell transplant, the stem cells come from a donor.

At this point, LeCours was a candidate for an autologous transplant. Once again, she underwent aggressive chemotherapy. A year later, the cancer returned.

Doctors told LeCours there wasnt much else they could do and advised her to get her affairs in order. But the hospitals transplant team felt she could be a candidate for an allogenic transplant. Theres risk rejecting donated stem cells can be fatal to the patient.

LeCours learned that her brother was a match. But the medical work-up would last about three months and she couldnt wait that long.

I wasnt sure I wanted to do it but I didnt have much choice, she said. They said, We have someone waiting in the wings.

And I said, He probably has wings.

After the transplant, LeCours recovered as an outpatient in the home of her brother and sister-in-law. It took three months to rebuild her immune system. Her only rejection symptoms were a bit of skin irritation.

In January 2018, LeCours received an email asking if she would like to exchange contact information with her donor. She replied that she would.

A few months later, she got a message with Whites co-ordinates and was astonished to find that her donor was in Ottawa. It took her a few weeks to formulate an email.

I didnt want to scare him. I just wanted him to know how incredibly grateful I was. And I wanted to pay it forward, said LeCours.

After careful consideration, she sent White an email on Oct. 8, 2018.

Today, being Thanksgiving, I have so much to be thankful for, namely you giving your stem cells and saving my life and the success of the stem cells grafting to my bone marrow, LeCours wrote. I cant thank you enough for your wonderful selfless act.

Stem cell donor 18-year-old Carleton University student Timothy White at The Ottawa Hospital, General campus, donating stem cells for Colleen LeCours in August 2016. At the time he did not know that LeCours would be the recipient. Courtesy Timothy White.jpg

She added that she didnt know anything about him except for his name and email address, and asked if they could meet. They got together for the first time over lunch in a burger restaurant.

As soon as I saw him, I broke down, said LeCours.

It has been three and a half years since the transplant and LeCours remains in remission. She invited White to her familys Thanksgiving this year, and the two meet to catch up every few months. Its one of the quirks of stem cell donation that the recipient assumes the blood type of the donor. LeCours, once O-positive, now has blood type A-negative, like White.

Im a grandmother. The fact that my grandson has his moma is huge.

ALSO IN THE NEWS

Ottawa police chief lifts suspension of police union boss Matt Skof

Reduce the burden: Inuit healing centre reopens after funding lapse forced shut down

RTG wasnt on top of it : New Years Eve light rail issues attributed to dirt, grit buildup on trains

Read more:
ASTRONOMICAL ODDS: Stem cell recipient and her donor both from Ottawa - Ottawa Sun